Favorable Media Coverage Somewhat Unlikely to Affect The Advisory Board (ABCO) Share Price
Media headlines about The Advisory Board (NASDAQ:ABCO) have been trending positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Advisory Board earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news stories about the business services provider an impact score of 45.6978911351487 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Hispanicize 2018 Organizers Announce National Advisory Board Leaders and Changes for 9th Annual Latino Trends Event (markets.financialcontent.com)
- Collective Health Expands Leadership and Advisory Board with Healthcare and HR Industry Leaders (markets.financialcontent.com)
- Voya Financial EVP of Operations Nan Ferrara Joins Advisory Board for Hofstra University’s Zarb School of Business (prnewswire.com)
- New Resource for Evidence to Prevent and End Homelessness (prweb.com)
- Sienna Biopharmaceuticals Establishes Corporate Advisory Board (markets.financialcontent.com)
Shares of The Advisory Board (NASDAQ:ABCO) opened at $53.83 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.07 and a quick ratio of 1.07. The stock has a market cap of $2,190.00, a PE ratio of 32.23, a PEG ratio of 2.40 and a beta of 1.34. The Advisory Board has a fifty-two week low of $30.40 and a fifty-two week high of $59.50.
A number of brokerages have recently issued reports on ABCO. Canaccord Genuity downgraded shares of The Advisory Board from a “buy” rating to a “hold” rating and lowered their price target for the stock from $56.00 to $54.29 in a report on Tuesday, August 29th. Wells Fargo & Company downgraded shares of The Advisory Board from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $57.00 to $54.00 in a report on Monday, October 2nd. Cantor Fitzgerald reissued a “hold” rating on shares of The Advisory Board in a report on Friday, November 17th. Robert W. Baird downgraded shares of The Advisory Board from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $63.00 to $54.00 in a report on Tuesday, August 29th. Finally, William Blair downgraded shares of The Advisory Board from an “outperform” rating to a “hold” rating in a report on Tuesday, August 29th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $51.95.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company offers subscription-based membership programs, software and data-enabled services. All of its programs are rooted in best practices and extends across four areas, including Best practices research, Technology, Data-enabled services and Consulting services.
Receive News & Ratings for The Advisory Board Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board and related companies with MarketBeat.com's FREE daily email newsletter.